See more : MPX International Corporation (MPXOF) Income Statement Analysis – Financial Results
Complete financial analysis of Aytu BioPharma, Inc. (AYTU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aytu BioPharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Eastern Metals Limited (EMS.AX) Income Statement Analysis – Financial Results
- PT TIMAH Tbk (TINS.JK) Income Statement Analysis – Financial Results
- adesso SE (ADSGF) Income Statement Analysis – Financial Results
- BEC World Public Company Limited (BECVY) Income Statement Analysis – Financial Results
- Career Design Center Co., Ltd. (2410.T) Income Statement Analysis – Financial Results
Aytu BioPharma, Inc. (AYTU)
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.00M | 107.40M | 96.67M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K | 58.93K | 1.75K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Cost of Revenue | 26.42M | 40.77M | 44.39M | 36.43M | 7.55M | 2.20M | 2.05M | 1.42M | 957.08K | 88.11K | 0.00 | -48.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 54.59M | 66.63M | 52.28M | 29.20M | 20.08M | 5.12M | 1.61M | 1.80M | 1.61M | 173.67K | 58.93K | 50.00K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 67.39% | 62.04% | 54.08% | 44.49% | 72.67% | 69.92% | 43.97% | 56.00% | 62.65% | 66.34% | 100.00% | 2,857.14% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 2.79M | 4.10M | 14.44M | 5.62M | 1.72M | 589.07K | 167.60K | 1.35M | 6.32M | 3.42M | 4.06M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.51M | 28.63M | 31.17M | 25.50M | 19.66M | 0.00 | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 0.00 |
| Selling & Marketing | 26.96M | 41.45M | 38.71M | 30.31M | 11.40M | 0.00 | 0.00 | -242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.47M | 70.08M | 69.88M | 55.81M | 34.80M | 19.24M | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 46.89K |
| Other Expenses | 7.58M | -4.78M | 4.07M | 6.01M | 4.49M | 2.14M | 6.28M | 1.71M | 664.71K | 4.89K | 6.18K | 6.18K | 7.34K | 4.25K | 2.58K | 2.71K | 0.00 | 0.00 |
| Operating Expenses | 60.57M | 78.96M | 88.39M | 67.44M | 41.01M | 21.96M | 19.45M | 20.66M | 15.81M | 7.81M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Cost & Expenses | 86.26M | 119.73M | 132.77M | 103.87M | 48.57M | 24.17M | 21.50M | 22.08M | 16.77M | 7.89M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Interest Income | 0.00 | 9.00K | 14.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.79M | 0.00 | 147.50M | 0.00 | 0.00 | 0.00 | 749.42K | 2.53M | 5.49M | 114.99K | 45.55K | 4.90K | 3.32K | 3.18K | 3.80K | 3.07K | 0.00 | 2.06K |
| Depreciation & Amortization | 8.27M | 8.82M | 10.15M | 7.70M | 4.59M | 2.24M | 1.85M | 1.84M | 874.79K | 118.20K | 97.48K | 4.94K | 6.15K | 6.76K | 9.19K | 8.28K | 7.52K | 6.42K |
| EBITDA | -1.01M | -3.51M | -27.96M | -29.04M | -12.21M | -14.12M | -15.25M | -18.13M | -21.81M | -7.51M | -52.71K | -47.47K | -50.21K | -126.86K | -47.28K | -47.54K | -47.47K | -40.47K |
| EBITDA Ratio | -1.25% | -7.07% | 42.70% | -22.08% | -89.07% | -59.69% | -245.22% | -449.95% | -520.19% | -2,870.37% | -10,604.89% | -2,712.69% | -2,868.91% | 0.00% | 0.00% | -2,716.51% | 0.00% | 0.00% |
| Operating Income | -5.25M | -17.07M | 37.22M | -38.24M | -20.94M | -16.85M | -19.70M | -20.13M | -21.70M | -7.63M | -6.35M | -52.41K | -56.36K | -133.62K | -56.74K | -55.82K | -54.98K | -46.89K |
| Operating Income Ratio | -6.49% | -15.89% | 38.50% | -58.26% | -75.76% | -230.13% | -538.26% | -624.70% | -847.02% | -2,915.53% | -10,770.31% | -2,995.09% | -3,220.34% | 0.00% | 0.00% | -3,189.83% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.82M | 14.00K | 1.02M | 840.00K | 7.51M | -10.29M | 9.51M | -2.38M | -6.48M | -114.99K | -4.23K | -4.90K | -3.32K | -3.18K | -3.53K | -3.07K | -2.19K | -2.06K |
| Income Before Tax | -14.08M | -17.05M | -110.28M | -58.03M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.75M | -6.39M | -57.32K | -59.68K | -136.80K | -56.47K | -58.89K | -48.95K | -48.95K |
| Income Before Tax Ratio | -17.38% | -15.88% | -114.08% | -88.42% | -49.29% | -370.64% | -278.36% | -698.67% | -1,099.73% | -2,959.45% | -10,847.61% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| Income Tax Expense | 1.77M | -57.00K | -110.00K | 259.00K | -9.92M | 20.04M | -2.13M | 1.11M | 8.48M | -23.91K | -813.70K | 911.31K | 3.32K | 3.18K | -548.00 | 3.07K | 2.19K | 2.06K |
| Net Income | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M | -47.17M | -10.19M | -22.51M | -28.18M | -7.72M | -5.58M | -57.32K | -59.68K | -136.80K | -60.27K | -58.89K | -57.17K | -48.95K |
| Net Income Ratio | -19.56% | -15.88% | -113.97% | -88.81% | -13.39% | -644.33% | -278.36% | -698.67% | -1,099.73% | -2,950.32% | -9,466.80% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| EPS | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| EPS Diluted | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| Weighted Avg Shares Out | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
Where Do Hedge Funds Stand On Aytu BioScience, Inc. (AYTU)?
Acerus Pharmaceuticals Corporation (ASPCF) CEO Ed Gudaitis on Q2 2020 Results - Earnings Call Transcript
Acerus Reports Fiscal 2020 Second Quarter Financial Results
NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403
Acerus Announces Launch of NATESTO® Specialty Sales Team in the United States
Aytu Bioscience (NASDAQ:AYTU) Shares Gap Up to $1.34
Aclaris Therapeutics (NASDAQ:ACRS) versus Aytu Bioscience (NASDAQ:AYTU) Financial Analysis
Aytu BioScience: The Next Arbor Pharmaceuticals?
Source: https://incomestatements.info
Category: Stock Reports